SCHEMBL20766974

SCHEMBL20766974

CNS(=O)(=O)c1ccc(NC2CCCCC2)c(-c2ccn(C)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.45
ALOX15 P16050 2/20 0.40
YAP1 P46937 2/20 0.39
TEAD1 P28347 1/20 0.39
IRAK1 P51617 2/20 0.39
IRAK4 Q9NWZ3 2/20 0.39
LMNA P02545 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SYK P43405 1/20 0.37
TAS2R14 Q9NYV8 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
PTGS2 P35354 1/20 0.36
WNK1 Q9H4A3 1/20 0.36
MAPT P10636 1/20 0.36
CHEK1 O14757 1/20 0.36
NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20766196 0.89 BRD4 (0.56) BRD4YAP1IRAK1IRAK4SYK
SCHEMBL29901813 0.89 BRD4 (0.56) BRD4YAP1IRAK1IRAK4SYK
SCHEMBL20767361 0.85 BRD4 (0.43) BRD4ALOX15YAP1TEAD1LMNA
SCHEMBL20766526 0.83 YAP1 (0.57) BRD4ALOX15YAP1TEAD1LMNA
SCHEMBL30410106 0.82 BRD4 (0.43) BRD4ALOX15YAP1LMNAALDH1A1
SCHEMBL20766518 0.82 BRD4 (0.43) BRD4ALOX15YAP1LMNAALDH1A1
SCHEMBL20766210 0.81 BRD4 (0.41) BRD4ALOX15YAP1LMNAALDH1A1
SCHEMBL20766351 0.80 GPR39 (0.47) BRD4ALOX15YAP1LMNAALDH1A1
SCHEMBL30411184 0.80 GPR39 (0.47) BRD4ALOX15YAP1LMNAALDH1A1
SCHEMBL20767153 0.80 YAP1 (0.43) BRD4ALOX15YAP1TEAD1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
CN-111542315-B Benzosulfonyl compounds 维瓦斯治疗公司 2023-05-12 CN disclosed
EP-3691623-B1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS INC (US) 2022-10-05 EP disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 US disclosed
CN-111542315-A Benzosulfonyl compounds 维瓦斯治疗公司 2020-08-14 CN disclosed
EP-3691623-A1 BENZOSULFONYL COMPOUNDS Vivace Therapeutics, Inc. (US) 2020-08-12 EP disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 WO disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192865-B2 Benzosulfonyl compounds YAP1, TEAD2, TEAD1 BRD4 7/4885ALOX15 3108/4885YAP1 1/4885
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 BRD4 328/4885ALOX15 3548/4885YAP1 9/4885
US-20200354325-A1 BENZOSULFONYL COMPOUNDS YAP1, TEAD2, TEAD1 BRD4 7/4885ALOX15 3108/4885YAP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.